Resona Asset Management Co. Ltd. bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 37,260 shares of the medical research company's stock, valued at approximately $5,281,000.
Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Natera by 0.6% in the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock worth $1,752,611,000 after buying an additional 77,357 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Natera by 9.9% in the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after buying an additional 660,538 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after purchasing an additional 3,871,862 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company's stock valued at $287,908,000 after purchasing an additional 245,719 shares during the last quarter. Finally, Castle Hook Partners LP raised its holdings in shares of Natera by 7.2% during the fourth quarter. Castle Hook Partners LP now owns 1,222,578 shares of the medical research company's stock valued at $193,534,000 after purchasing an additional 82,488 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.
Natera Stock Performance
NTRA stock opened at $163.02 on Friday. Natera, Inc. has a one year low of $110.57 and a one year high of $183.00. The company's fifty day moving average price is $155.18 and its 200-day moving average price is $154.75. The company has a market capitalization of $22.37 billion, a PE ratio of -85.35 and a beta of 1.76.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. Natera's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.30) EPS. On average, research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research firms have recently weighed in on NTRA. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a report on Monday, July 28th. Barclays reissued an "overweight" rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a report on Friday, August 8th. Cowen reissued a "buy" rating on shares of Natera in a report on Friday, August 8th. Finally, UBS Group boosted their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and an average target price of $193.19.
Check Out Our Latest Stock Analysis on NTRA
Insiders Place Their Bets
In other news, insider Solomon Moshkevich sold 875 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $136,027.50. Following the sale, the insider owned 123,859 shares of the company's stock, valued at approximately $19,255,120.14. This represents a 0.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gail Boxer Marcus sold 2,496 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $133.17, for a total transaction of $332,392.32. Following the completion of the transaction, the director owned 5,763 shares in the company, valued at approximately $767,458.71. The trade was a 30.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 61,792 shares of company stock valued at $9,227,972. 5.63% of the stock is currently owned by company insiders.
Natera Profile
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
MarketBeat All Access